(VIANEWS) – MFA Financial (MFA), Bruker Corporation (BRKR), Royalty Pharma (RPRX) are the highest sales growth and return on equity stocks on this list.
Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?
1. MFA Financial (MFA)
37.5% sales growth and 5.14% return on equity
MFA Financial, Inc., together with its subsidiaries, operates as a real estate investment trust in the United States. The company invests in residential mortgage assets, including non-agency mortgage-backed securities, agency MBS, and credit risk transfer securities; residential whole loans, including purchased performing loans, purchased credit deteriorated, and non-performing loans; and mortgage servicing rights related assets. MFA Financial, Inc. was incorporated in 1997 and is based in New York, New York.
Earnings Per Share
As for profitability, MFA Financial has a trailing twelve months EPS of $0.63.
PE Ratio
MFA Financial has a trailing twelve months price to earnings ratio of 19.21. Meaning, the purchaser of the share is investing $19.21 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 5.14%.
Sales Growth
MFA Financial’s sales growth is 35% for the present quarter and 37.5% for the next.
2. Bruker Corporation (BRKR)
18.6% sales growth and 22.86% return on equity
Bruker Corporation develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States and internationally. The company operates through three segments: Bruker Scientific Instruments (BSI) Life Science, BSI NANO, and Bruker Energy & Supercon Technologies. It offers life science tools, and single and multiple modality systems; life science mass spectrometry; MALDI Biotyper rapid pathogen identification platform and related test kits, DNA test strips, and fluorescence-based polymerase chain reaction technology; genotype and fluorotype molecular diagnostics kits; research, analytical, and process analysis instruments and solutions; SARS-CoV 2 testing for the diagnosis of COVID-19 infection; and Fluorotyper-SARS-CoV 2 plus kits. It also provides range of portable analytical and bioanalytical detection systems, and related products; X-ray instruments; analytical tools for electron microscopes, as well as handheld, portable, and mobile X-ray fluorescence spectrometry instruments; atomic force microscopy instrumentation; non-contact nanometer resolution solution topography; and automated X-ray metrology, automated AFM defect-detection, and photomask repair and cleaning equipment. In addition, the company offers advanced optical fluorescence microscopy instruments; products and services to support the multi-omics needs of researchers in translational research, drug, and biomarker discovery; superconducting materials, such as metallic low temperature superconductors; devices and complex tools based on metallic low temperature superconductors; and non-superconducting high technology tools, such as synchrotron and beamline instrumentation. Bruker Corporation has a collaboration with Newomics Inc. on a LC-MS platform for drug discovery. The company was incorporated in 1991 and is headquartered in Billerica, Massachusetts.
Earnings Per Share
As for profitability, Bruker Corporation has a trailing twelve months EPS of $2.39.
PE Ratio
Bruker Corporation has a trailing twelve months price to earnings ratio of 28.28. Meaning, the purchaser of the share is investing $28.28 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 22.86%.
Yearly Top and Bottom Value
Bruker Corporation’s stock is valued at $67.59 at 16:22 EST, way under its 52-week high of $94.86 and way above its 52-week low of $53.79.
Dividend Yield
As maintained by Morningstar, Inc., the next dividend payment is on Aug 30, 2024, the estimated forward annual dividend rate is 0.2 and the estimated forward annual dividend yield is 0.3%.
3. Royalty Pharma (RPRX)
15.6% sales growth and 10.53% return on equity
Earnings Per Share
As for profitability, Royalty Pharma has a trailing twelve months EPS of $2.53.
PE Ratio
Royalty Pharma has a trailing twelve months price to earnings ratio of 11.15. Meaning, the purchaser of the share is investing $11.15 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 10.53%.
4. Churchill Downs (CHDN)
15% sales growth and 43.06% return on equity
Churchill Downs Incorporated operates as a racing, online wagering, and gaming entertainment company in the United States. It operates through three segments: Live and Historical Racing, TwinSpires, and Gaming. As of December 31, 2021, the company owned and operated three pari-mutuel gaming entertainment venues with approximately 3,050 historical racing machines (HRMs) in Kentucky; TwinSpires, an online wagering platform for horse racing, sports, and iGaming; nine retail sportsbooks; and casino gaming in eight states with approximately 11,000 slot machines and video lottery terminals, and 200 table games. It also offers streaming video of live horse races, replays, and an assortment of racing and handicapping information; and provides the Bloodstock Research Information Services platform for horse racing statistical data. In addition, the company manufactures and operates pari-mutuel wagering systems for racetracks, off-track betting facilities, and other pari-mutuel wagering businesses. Churchill Downs Incorporated was founded in 1875 and is headquartered in Louisville, Kentucky.
Earnings Per Share
As for profitability, Churchill Downs has a trailing twelve months EPS of $5.46.
PE Ratio
Churchill Downs has a trailing twelve months price to earnings ratio of 25.45. Meaning, the purchaser of the share is investing $25.45 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 43.06%.
Moving Average
Churchill Downs’s value is higher than its 50-day moving average of $138.71 and higher than its 200-day moving average of $128.51.
Sales Growth
Churchill Downs’s sales growth for the next quarter is 15%.
Volume
Today’s last reported volume for Churchill Downs is 211970 which is 53.43% below its average volume of 455182.
Growth Estimates Quarters
The company’s growth estimates for the ongoing quarter and the next is 21.8% and 26.7%, respectively.
5. BioMarin Pharmaceutical (BMRN)
13.8% sales growth and 5.1% return on equity
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme, which is delivered through subcutaneous injection to reduce blood Phe concentrations; Brineura, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; Voxzogo, a once daily injection analog of c-type natriuretic peptide for the treatment of achondroplasia; and Aldurazyme, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase. In addition, it develops valoctocogene roxaparvovec, an adeno associated virus vector, which is in Phase III clinical trial for the treatment of patients with severe hemophilia A; BMN 307, an AAV5 mediated gene therapy, which is in Phase 1/2 clinical trial to normalize blood Phe concentration levels in patients with PKU; and BMN 255 that is in Phase 1/2 clinical trial for treating primary hyperoxaluria. The company serves specialty pharmacies, hospitals, and non-U.S. government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. BioMarin Pharmaceutical Inc. has license and collaboration agreements with Sarepta Therapeutics, Ares Trading S.A., Catalyst Pharmaceutical Partners, Inc., and Asubio Pharma Co., Ltd. The company was incorporated in 1996 and is headquartered in San Rafael, California.
Earnings Per Share
As for profitability, BioMarin Pharmaceutical has a trailing twelve months EPS of $1.32.
PE Ratio
BioMarin Pharmaceutical has a trailing twelve months price to earnings ratio of 69.22. Meaning, the purchaser of the share is investing $69.22 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 5.1%.
Moving Average
BioMarin Pharmaceutical’s worth is above its 50-day moving average of $86.04 and above its 200-day moving average of $87.34.
Volume
Today’s last reported volume for BioMarin Pharmaceutical is 1495240 which is 34.25% below its average volume of 2274230.
Growth Estimates Quarters
The company’s growth estimates for the ongoing quarter and the next is 152.4% and 418.2%, respectively.
Previous days news about BioMarin Pharmaceutical(BMRN)
- According to Zacks on Wednesday, 28 August, "Our proprietary system currently recommends BioMarin Pharmaceutical (BMRN Quick QuoteBMRN – Free Report) as one such stock. "
6. Credicorp Ltd. (BAP)
13.1% sales growth and 15.79% return on equity
Credicorp Ltd., a financial services holding company, provides various financial, insurance, and health services and products primarily in Peru and internationally. The company's Universal Banking segment offers deposits and current accounts, and various credits and financial instruments to individuals and legal entities. Its Insurance and Pensions segment issues insurance policies to cover losses in commercial property, transportation, marine vessels, automobile, life, health, and pensions, as well as provides private pension fund management services. The company's Microfinance segment manages loans, credits, deposits, and current accounts of the small and microenterprises. Its Investment Banking and Wealth Management segment offers its services to corporations, institutional investors, governments, and foundations; engages in structuring and placement of issues in the primary market, as well as the execution and negotiation of operations in the secondary market; and structures securitization processes for corporate customers and manages mutual funds. The company was founded in 1889 and is headquartered in Lima, Peru.
Earnings Per Share
As for profitability, Credicorp Ltd. has a trailing twelve months EPS of $16.2.
PE Ratio
Credicorp Ltd. has a trailing twelve months price to earnings ratio of 10.47. Meaning, the purchaser of the share is investing $10.47 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 15.79%.
Revenue Growth
Year-on-year quarterly revenue growth grew by 5.4%, now sitting on 16.72B for the twelve trailing months.
7. Universal Stainless & Alloy Products (USAP)
6.3% sales growth and 7.6% return on equity
Universal Stainless & Alloy Products, Inc., together with its subsidiaries, manufactures and markets semi-finished and finished specialty steel products in the United States and internationally. Its products include stainless steel, nickel alloys, tool steel, and various other alloyed steels. The company offers semi-finished and finished long products in the form of ingots, blooms, billets, and bars; flat rolled products, such as slabs and plates; and customized shapes primarily for original equipment manufacturers (OEMs), which are cold rolled from purchased coiled strip, flat bar, or extruded bar. Its semi-finished long products are primarily used to produce rods; and finished bar products that are principally used by OEMs and by service center customers for distribution to various end users. The company also offers conversion services on materials supplied by its customers. Its products are used in aerospace, power generation, oil and gas, heavy equipment, general, and automotive industries, as well as in the manufacturing of equipment for food handling, health and medical, chemical processing, and pollution control; and manufacturing of metals, plastics, paper and aluminum extrusions, pharmaceuticals, electronics, and optics. The company sells its products to service centers, forgers, rerollers, and OEMs. Universal Stainless & Alloy Products, Inc. was founded in 1994 and is headquartered in Bridgeville, Pennsylvania.
Earnings Per Share
As for profitability, Universal Stainless & Alloy Products has a trailing twelve months EPS of $1.82.
PE Ratio
Universal Stainless & Alloy Products has a trailing twelve months price to earnings ratio of 21.66. Meaning, the purchaser of the share is investing $21.66 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 7.6%.
Moving Average
Universal Stainless & Alloy Products’s value is way above its 50-day moving average of $31.92 and way higher than its 200-day moving average of $24.49.
8. Elbit Systems Ltd. (ESLT)
5.3% sales growth and 8.37% return on equity
Elbit Systems Ltd. develops and supplies a portfolio of airborne, land, and naval systems and products for the defense, homeland security, and commercial aviation applications primarily in Israel, North America, the Asia-Pacific, Europe, Latin America, and internationally. The company operates through five segments: Aerospace; C4I and Cyber; Intelligence, Surveillance, Target Acquisition and Reconnaissance (ISTAR) and Electronic Warfare (EW); Land; and Elbit Systems of America (ESA). It also offers military aircraft and helicopter systems; commercial aviation systems and aerostructures; unmanned aircraft systems; flight academy solutions, electro-optic, night vision, high power energy solutions, and countermeasures systems; naval systems; land vehicle systems; munitions, such as precision munitions for land, air, and sea applications; command, control, communications, computer, intelligence, surveillance and reconnaissance, and cyber systems; electronic warfare and signal intelligence systems; and other commercial activities. In addition, the company manufactures and sells data links and radio communication systems and equipment, and cyber intelligence, autonomous, and homeland security solutions. Further, it provides various electronic warfare and signal intelligence systems, and laser systems; armored vehicle and other platforms survivability and protection systems, artillery, and mortar systems, as well as provides various training and support services. Additionally, the company offers products and systems solutions to military, foreign military sales, homeland security, medical instrumentation, and commercial aviation clients. It markets its systems and products as a prime contractor or subcontractor to various governments and companies. The company was incorporated in 1966 and is based in Haifa, Israel.
Earnings Per Share
As for profitability, Elbit Systems Ltd. has a trailing twelve months EPS of $5.44.
PE Ratio
Elbit Systems Ltd. has a trailing twelve months price to earnings ratio of 37.57. Meaning, the purchaser of the share is investing $37.57 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 8.37%.
Sales Growth
Elbit Systems Ltd.’s sales growth is 7.1% for the present quarter and 5.3% for the next.
Revenue Growth
Year-on-year quarterly revenue growth grew by 11.8%, now sitting on 6.31B for the twelve trailing months.
